PT-141 / Bremelanotide
A melanocortin receptor agonist; bremelanotide is FDA approved for one narrowly defined indication under the Vyleesi label.
On this page
WHAT THE EVIDENCE SAYS
PT-141 / Bremelanotide evidence summary.
PT-141 is commonly marketed more broadly than the evidence allows. The decision-grade record concerns FDA-reviewed bremelanotide, its subcutaneous formulation, and one narrow population and indication.
01 / CLASSIFICATION
What is PT-141 / Bremelanotide?
Names, fragments, salts, formulations, routes, and branded products are kept distinct whenever transferring evidence would change the conclusion.
02 / EVIDENCE
PT-141 / Bremelanotide human and preclinical evidence.
The five-point bars describe the maturity and depth of the evidence base. They do not score effectiveness, safety, or personal suitability.
03 / STATUS
PT-141 / Bremelanotide FDA and sport status.
Status summaries are educational and time-sensitive. Consult current official labeling and anti-doping resources for a decision.
04 / RESEARCH AREAS
What is PT-141 / Bremelanotide being studied for?
05 / COMPARISONS
Compare PT-141 / Bremelanotide.
06 / LATEST & DEFINING SOURCES
PT-141 / Bremelanotide primary and official sources.
07 / QUESTIONS
Questions about PT-141 / Bremelanotide.
Start with identity, research, human evidence, approval, sport status, and the limits of the current record.
PT-141 is commonly marketed more broadly than the evidence allows. The decision-grade record concerns FDA-reviewed bremelanotide, its subcutaneous formulation, and one narrow population and indication.
Current source-backed research areas include Hypoactive sexual desire disorder, Melanocortin receptors, Sexual distress, Female sexual health. These areas describe investigation, not established personal benefit.
Current U.S. status for PT-141 / Bremelanotide: Bremelanotide is FDA approved as Vyleesi only for premenopausal women with acquired, generalized hypoactive sexual desire disorder; it is not indicated for men, postmenopausal women, or sexual performance enhancement.
Current sport-status snapshot for PT-141 / Bremelanotide: Not specifically named in the 2026 WADA List; athletes should verify current status and product contents.
An approval for Vyleesi does not validate every product sold as PT-141 or use in populations outside the label.